top of page

Dr. WONG Chi Yan, Ashley

MBBS (HK), MRCP (UK), FHKAM (Med), FHKCP (Med Onc)

Associate Consultant (QMH)
Honorary Clinical Assistant Professor


Dr. Wong graduated from the University of Hong Kong, Faculty of Medicine in 2007. She received  basic physician training in Department of Medicine, Queen Mary Hospital  and higher physician training in medical oncology in  Department of Clinical Oncology, Princes of Wales Hospital.
She is currently associate consultant in Medical Oncology at Queen Mary Hospital, Hong Kong.  Her research interests include breast cancer and palliative care.

Five Most Representative Publications

1) A Wong, B Ma
Personalizing therapy for colorectal cancer.
Clin Gastroenterol Hepatol. 2014 Jan;12(1):139-44

[Citation: 34 ] [IF: 7.40 (JCR 2016)]  

2) A Wong, B Ma
An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1255-61

[Citation: 9 ] [IF: 3.03 (JCR 2016)]  

3) Wong CY, Tsang KW, Li CW, Au HY, Chan KY.
Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.
AME Case Rep. 2021 Jan 25;5:7. doi: 10.21037/acr-20-108. PMID: 33634247; PMCID: PMC7882262.

[Citation: - ] [IF: NA]  

4) Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J.

Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer

Postgrad Med J. 2021 May 26 doi:10.1136/postgradmedj-2021-140319

[Citation: -] [IF: 2.40 (JCR 2020)] 

bottom of page